P325: Performance of new MRI scores: the modified Van Assche Index and the MAGNIFI-CD in the evaluation of the response to anti-TNFα in anoperineal fistulas in Crohn's diseaseECCO'22Year: 2022
Authors: Mtir, M.(1);Hassine, H.(1);Kahlaoui, F.(1);Cherif, D.(1);Tlili, R.(1);Kchir, H.(1);Maamouri, N.(1);
(1)La Rabta hospital, department of gastro-enterology B, Tunis, Tunisia;
P326: The effect of compliance during exclusive enteral nutrition on faecal calprotectin levels in children with Crohn’s diseaseECCO'22Year: 2022
Authors: Mckirdy, S.(1);Russell, R.(2);Hansen, R.(3);Svolos, V.(1);Gkikas, K.(1);Logan, M.(1);Gerasimidis, K.(1);
(1)University of Glasgow, Human Nutrition, Glasgow, United Kingdom;(2)Royal Hospital for Children and Young People, Department of Paediatric Gastroenterology, Edinburgh, United Kingdom;(3)Royal Hospital for Children, Department of Paediatric Gastroenterology, Glasgow, United Kingdom;
P327: Comparison of adalimumab drug levels and drug survival in proactive vs reactive therapeutic drug monitoringECCO'22Year: 2022
Authors: Shields, S.(1);Dunlop, A.(2);Barry, S.(3);Galloway, P.(2);Seenan, J.P.(1);Macdonald, J.(1);
(1)Queen Elizabeth University Hospital, Gastroenterology, Glasgow, United Kingdom;(2)Queen Elizabeth University Hospital, Biochemistry, Glasgow, United Kingdom;(3)University of Strathclyde, Department of Mathematics and Statistics, Glasgow, United Kingdom;
P328: In silico evaluation and pre-clinical efficacy of anti-TNF and anti-IL-23 combination therapy in Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: Perrigoue, J.(1);Muniz-Bongers, L.(1);Ong, L.(1);Chen, Y.(2);Chang, L.(2);Ngo, K.(2);Stojmirovic, A.(1);O’Brien, C.(1);Germinaro, M.(1);Rao, R.(1);Vetter, M.(1);Towne, J.(2);
(1)Janssen Research & Development- LLC, Immunology, Spring House, United States;(2)Janssen Research & Development- LLC, Immunology, San Diego, United States;VEGA
P329: Which should come first? Surgery or biologic therapy for ileocaecal Crohn’s disease in biologic naïve patientsECCO'22Year: 2022
Authors: Witjes, C.(1,2);Patel, A.(1,3);Zocche, D.(1);van 't Hullenaar- , C.(1);Cripps, S.(4);Travis, S.(5);George, B.(1);
(1)Oxford University Hospital- NHS Foundation Trust- Oxford, Department of Colorectal surgery, Oxford, United Kingdom;(2)Ijsselland Hospital, Department of General Surgery and Colorectal Surgery-, Capelle aan den IJssel, The Netherlands;(3)University hospital of Coventry and Warwickshire NHS Trust, Department of Colorectal surgery, Coventry, United Kingdom;(4)Oxford University Hospital- NHS Foundation Trust, Pharmacy Department – Gastroenterology/Hepatology, Oxford, United Kingdom;(5)Oxford University Hospital- NHS Foundation Trust, Translational Gastroenterology Unit, Oxford, United Kingdom;
P330: Immunity in patients with inflammatory bowel disease on biologic therapy after COVID 19 vaccinationECCO'22Year: 2022
Authors: Knezevic, T.(1);Cujic, D.(2);Odanovic, O.(1);Kralj, D.(1);Gnjatovic, M.(2);Kalaba, A.(1);Vrinic Kalem, D.(1);Svorcan, P.(1,3);Markovic, S.(1,3);
(1)University Hospital Zvezdara, Gastroenterology and hepatology, Belgrade, Serbia;(2)Institute for Application of Nuclear Energy, University of Belgrade, Belgrade, Serbia;(3)School of Medicine, University of Belgrade, Belgrade, Serbia;
P331: Composite outcomes in Crohn’s disease: a systematic review and meta-analysis of observational studiesECCO'22Year: 2022
Authors: Estevinho, M.M.(1);Sottomayor, C.(2);Alves, C.(3);Santago, M.(4);Ministro, P.(5);Lago, P.(6);Correia, L.(7);Gonçalves, R.(8);Carvalho, D.(9);Portela, F.(10);Dias, C.C.(11);Dignass, A.(12);Danese, S.(13);Peyrin-Biroulet, L.(14);Magro, F.(15);
(1)Centro Hospitalar Vila Nova de Gaia/Espinho, Department of Gastroenterology, Vila Nova de Gaia, Portugal;(2)Unit of Pharmacology and Therapeutics- Faculty of Medicine- University of Porto, Department of Biomedicine-, Porto, Portugal;(3)Unit of Pharmacology and Therapeutics- Faculty of Medicine- University of Porto, Department of Biomedicine, Porto, Portugal;(4)Center for Health Technology and Services Research CINTESIS, Biomedicine, Porto, Portugal;(5)Centro Hospitalar Tondela-Viseu, Department of Gastroenterology, Viseu, Portugal;(6)Porto Hospital Center- Hospital de Santo António, Department of Gastroenterology, Porto, Portugal;(7)Lisbon North Hospital Centre- Santa Maria Hospital, Department of Gastroenterology, Lisbon, Portugal;(8)Hospital de Braga, Department of Gastroenterology, Braga, Portugal;(9)Santo António dos Capuchos Hospital at Centro Hospitalar Lisboa Central, Department of Gastroenterology, Lisbon, Portugal;(10)University Hospital Centre of Coimbra, Department of Gastroenterology, Coimbra, Portugal;(11)Information and Health Decision Sciences- Faculty of Medicine- University of Porto, Department of Community Medicine, Porto, Portugal;(12)Agaplesion Markus Hospital- Dept. of Medicine I, Gastroenterology, Frankfurt, Germany;(13)Humanitas Clinical and Research Center IRCCS, Inflammatory Bowel Disease IBD Center- Department of Gastroenterology-, Milan, Italy;(14)University Hospital of Nancy- University of Lorraine, Department of Gastroenterology and Inserm NGERE U1256-, Vandoeuvre-lès-Nancy, France;(15)São João University Hospital Center CHUSJ, epartment of Gastroenterology, Porto, Portugal;GEDII - Portuguese IBD Group
P332: Group-based Acceptance and Commitment Therapy (ACT) is acceptable and effective at reducing psychological distress in patients with Inflammatory Bowel Disease (IBD).ECCO'22Year: 2022
Authors: Duff, A.(1);De Petrillo, A.(2);Reynolds, D.(3);Bangura, E.(4);Pavilidis, P.(1);Mawdsley, J.(1);
(1)Guy's and St. Thomas hospital- London, Gastroenterology, London, United Kingdom;(2)King's College Hospital- London, Pediatrics, London, United Kingdom;(3)Guy's and St. Thomas hospital- London, Pediatrics, London, United Kingdom;(4)Kings College, Clinical Psychology, London, United Kingdom;
P333: Precise and unbiased infliximab dosing in patients with inflammatory bowel diseases using a multi-model averaging approachECCO'22Year: 2022
Authors: Kantasiripitak, W.(1);Outtier, A.(2,3);Thomas, D.(1);Kensert, A.(1);Wang, Z.(1);Sabino, J.(2,3);Wicha, S.G.(4);Vermeire, S.(2,3);Ferrante, M.(2,3);Dreesen, E.(1);
(1)University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)University of Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(4)University of Hamburg, Department of Clinical Pharmacy, Hamburg, Germany;
P334: Effectiveness and safety of ustekinumab in Crohn’s disease: short and long-term results of a multi-refractory cohort.ECCO'22Year: 2022
Authors: Aparicio-Serrano, A.(1);Zamora Olaya, J.M.(1);Ortiz Chimbo, D.S.(1);Rodríguez Tirado, M.I.(1);Gómez Pérez, A.(1);Soto Escribano, P.(1);Marín Pedrosa, S.(1);Iglesias Flores, E.(1);Benítez, J.M.(1);
(1)Reina Sofía University Hospital, Gastroenterology and Hepatology, Córdoba, Spain;
P335: Utility of Intestinal Ultrasound in Monitoring Disease Activity in Ulcerative Colitis Patients Treated with BiologicsECCO'22Year: 2022
Authors: Tomašić, V.(1);Kralj, D.(1);Bišćanin, A.(1);Ćaćić, P.(1);Ogresta, D.(1);Dorosulić, Z.(1);Hrabar, D.(1);
(1)University Hospital Centre Sestre milosrdnice, Department of Gastroenterology and Hepatology, Zagreb, Croatia;
P336: Can Mesenchymal Stem Cell (MSC) apoptosis be used as a biomarker for treatment success in perianal fistulising Crohn’s Disease (pCD)? Findings from a prospective pilot studyECCO'22Year: 2022
Authors: Iqbal, N.(1,2);Constable, L.(3,4);Tozer, P.(1,2);Lung, P.(1);Hart, A.(1,4);Powell, N.(4);
(1)St Mark's Hospital, Robin Phillips Fistula Research Unit, London, United Kingdom;(2)Imperial College London, Department of Surgery and Cancer, London, United Kingdom;(3)Kings College London, Department of Inflammation Biology- School of Immunology and Microbial Science, London, United Kingdom;(4)Imperial College London, Department of Metabolism- Digestion and Reproduction, London, United Kingdom;
P338: Early proactive drug monitoring strategy of infliximab as monotherapy for inflammatory bowel disease in paediatric patients is associated with good sustained clinical remissionECCO'22Year: 2022
Authors: Girard, C.(1);Achkar, S.(2);Sassine, S.(2);Chapuy, L.(3);Jantchou, P.(1);Deslandres, C.(1);
(1)CHU Sainte-Justine- Université de Montréal, Department of Pediatrics. Division of Gastroenterology-Hepatology and Nutrition, Montreal, Canada;(2)Université de Montréal, Faculty of medecine, Montreal, Canada;(3)Montreal Children’s Hospital- McGill University, Department of Pediatrics. Division of Gastroenterology- Hepatology- and Nutrition., Montreal, Canada;
P339: Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: TheodorakiMD- MA- PhD c, E.(1);Orfanoudaki, E.(1);Foteinogiannopoulou, K.(1);Andreou, N.P.(2);Gazouli, M.(2);Koutroubakis, I.(1);
(1)University Hospital of Heraklion- School of Medicine, Department of Gastroenterology, Heraklion, Greece;(2)Laboratory of Biology- School of Medicine- National and Kapodistrian University of Athens, Department of Basic Medical Sciences, Anthens, Greece;
P341: Pharmacokinetics and exposure-response analyses of upadacitinib in patients with moderate to severe ulcerative colitis – Analyses of induction and maintenance clinical trialsECCO'22Year: 2022
Authors: Ponce-Bobadilla, A.V.(1);Stodtmann, S.(1);Eckert, D.(1);Zhou, W.(2);Liu, W.(2);Mohamed, M.E.(2);
(1)AbbVie Deutschland GmbH & Co. KG, Research and Development, Ludwigshafen, Germany;(2)AbbVie, Research and Development, North Chicago- IL, United States;
P342: Trans-continental analysis of over 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD ConsortiumECCO'22Year: 2022
Authors: Wong, S.Y.(1);Helmus, D.(2);Marlow, L.(3);Martinez Pazos, V.(2);Brann, S.(3);Wellens, J.(4);Kedia, S.(5);Mak , J.W.Y.(6);Bergemalm, D.(7);Argollo, M.(8);Zaltman, C.(9);Steinwurz, F.(10);Rubin, D.(11);Allez, M.(12);Halfvarson, J.(7);Abreu, M.T.(13);Lindsay, J.(14);Dutta, U.(15);Silverberg, M.S.(16);Ng, S.C.(6);Ahuja, V.(5);Watanabe, K.(17);Vermeire, S.(18);Colombel, J.F.(2);Satsangi, J.(19);
(1)Mount Sinai Hospital, The Henry D. Janowitz Division of Gastroenterology- Department of Medicine, New York, United States;(2)Icahn School of Medicine at Mount Sinai, The Henry D. Janowitz Division of Gastroenterology- Department of Medicine, New York, United States;(3)University of Oxford, Translational Gastro-Intestinal Unit- Nuffield Department of Medicine, Oxford, United Kingdom;(4)University Hospitals Leuven, Translational Research for Gastrointestinal Diseases, Leuven, Belgium;(5)All India Institute of Medical Sciences, Gastroenterology, New Delhi, India;(6)The Chinese University of Hong Kong, Medicine and Therapeutics, Hong Kong, China;(7)Örebro University, Dept of Gastroenterology- Faculty of Medicine and Health, Örebro, Sweden;(8)Universidade Federal de São Paulo, Department of Gastroenterology, São Paulo, Brazil;(9)Hospital Universitário- Universidade Federal Do Rio de Janeiro, Departamento de Clínica Médica, Rio de Janeiro, Brazil;(10)Instituto Steinwurz de Saúde do Intestino, Division of Gastroenterology and Hepatology, São Paulo, Brazil;(11)The University of Chicago, Gastroenterology- Hepatology & Nutrition, Chicago, United States;(12)Hôpital Saint-Louis- APHP- Université de Paris, Gastroenterology, Paris, France;(13)University of Miami Miller School of Medicine, Gastroenterology- Department of Medicine, Miami, United States;(14)Barts Health NHS Trust – The Royal London Hospital, Centre for Immunobiology, London, United Kingdom;(15)Postgraduate Institute of Medical Education & Research, Gastroenterology, Chandigarh, India;(16)University of Toronto, Division of Gastroenterology- Mount Sinai Hospital Inflammatory Bowel Disease Centre, Toronto, Canada;(17)Hyogo College of Medicine, Center for Inflammatory Bowel Disease- Division of Internal Medicine, Nishinomiya, Japan;(18)University Hospital Leuven and Catholic University Leuven, Gastroenterology & Hepatology, Leuven, Belgium;(19)University of Oxford, Nuffield Department of Medicine, Oxford, United Kingdom;ICARUS-IBD Consortium
P343: Changing the coUrse of cRohn’s disease with an Early use of adalimumab: The CURE study from the GETAIDECCO'22Year: 2022
Authors: Peyrin-Biroulet, L.(1);Bouhnik, Y.(2);Laharie, D.(3);Elgharabawy, Y.(4);
(1)CHRU de Nancy, Gastroenterology, Nancy, France;(2)AP-HP. Nord-Université de Paris- Hôpital Beaujon, Gastroenterology, Clichy, France;(3)CHU Bordeaux Haut Lévèque, Gastroenterology, Pessac, France;(4)GETAID, Biostatistic, Paris, France;the CURE GETAID study group
P344: What our patients are looking for - the common fields of interest in IBD patients: A Google Trends AnalysisECCO'22Year: 2022
Authors: Zarchi, R.(1);Elgressy, A.(2);Ben-Horin, S.(2);Kopylov, U.(2);
(1)Tel Aviv University, Sackler School of Medicine., Tel Aviv, Israel;(2)Tel-HaShomer Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;
P345: The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn’s DiseaseECCO'22Year: 2022
Authors: Macaluso, F.S.(1);Grova, M.(1);Saladino, M.(2);Demarzo, M.G.(3);Privitera, A.C.(4);Giangreco, E.(5);Garufi, S.(6);Renna, S.(1);Casà, A.(1);Ventimiglia, M.(7);Cappello, M.(2);Fries, W.(3);Orlando, A.(1);
(1)Ospedali Riuniti Villa Sofia-Cervello, IBD Unit, Palermo, Italy;(2)University of Palermo, Gastroenterology and Hepatology Section- Promise-, Palermo, Italy;(3)University of Messina, IBD Unit, Messina, Italy;(4)Cannizzaro Hospital, IBD Unit, Catania, Italy;(5)Guzzardi Hospital, Gastroenterology Unit, Vittoria, Italy;(6)A.R.N.A.S. “Garibaldi”, Gastroenterology Unit-, Catania, Italy;(7)Italian Ministry of Health, Directorate General of Medical Device and Pharmaceutical Service, Rome, Italy;Sicilian Network for Inflammatory Bowel Disease (SN-IBD)
